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Summary Local recurrence of colorectal cancer may result from failure to assess accurately the extent of
tumour at operation. It has been suggested that peroperative radioimmunolocalisation may improve this
assessment. The degree to which this is possible has been studied using a hand-held gamma detecting probe
and comparing two '25I-labelled monoclonal antibodies to colorectal tumours. The antibodies were to fetal
colonic microvillus membrane (FMID10) and to carcinoembryonic antigen (A5B7). Sixty-nine per cent (9/13)
of the FMlDIO and 98% (43/44) of A5B7 labelled tumours took up significant amounts of antibody with a
tumour to normal colon ratio of more than 1.5:1. The uptake was significantly better for A5B7 with a median
tumour to normal colon ratio of 3.3 (1.1-13.8) compared to 1.85 (0.75-7.7) for FMlDIO (P<0.001). The
tumour: colon ratio of both antibodies was independent of the serum CEA, Dukes' stage or the degree of
histological differentiation. There was a linear correlation for tumour to normal colon ratios between the
gamma detecting probe and the same tissue examined in a conventional well counter (correlation coefficient
r = 0.78, P<0.001). Colorectal tumours demonstrate a rapid and reliable uptake of anti-CEA monoclonal
antibody ASB7. This antibody can be detected with a peroperative gamma detecting probe and has the
potential to improve the surgeon's appreciation of the extent of tumour and therefore may influence the
surgery performed. Detailed clinical studies are now being carried out.
The cure of colorectal carcinoma is dependent on adequate
primary surgery. Failure to appreciate the extent of the
tumour may result in inadequate clearance and subsequent
local recurrence (Heald & Ryall, 1986; Turnbull et al., 1967).
While multiple frozen sections or cytology may help deter-
mine the spread of tumour this is time consuming and not
widely practised.
Peroperative radioimmunolocalisation offers an alternative
method of assessing the extent of tumour present.
Radiolabelled antibodies to colorectal tumours may be
administered intravenously preoperatively and then the dist-
ribution of antibody determined at operation using a sterile
hand-held gamma detecting probe. The technique depends on
reliable uptake of antibody by the tumour at a significantly
higher rate than the surrounding tissues.
Previous studies have used a mouse monoclonal antibody
to a cell surface antigen of mammary carcinoma metastasis
(B72.3), and a polyclonal baboon antibody to carcinoemb-
ryonic antigen (CEA) (Aitken et al., 1984; Martin et al.,
1985; O'Dwyer et al., 1986; Martin et al., 1986; O'Dwyer et
al., 1987). Only 72-76% of tumours in these patients had
significant uptake of these antibodies and the mean time
needed for adequate concentration of antibody in tumour
compared to normal tissue was 16 days.
In order to improve on these results the characteristics of
an ideal antibody would be: (a) that it is taken up by all
tumour deposits; (b) the uptake should be rapid so that
surgery does not have to be delayed; and (c) the antibody
should achieve as high a tumour to normal tissue ratio as
possible to enable small quantities of tumour to be detected.
We have therefore compared two different antibodies in 50
consecutive patients, first to validate the method of
peroperative radioimmunolocalisation and second to assess
which of these antibodies has the better characteristics.
Patients and methods
Fifty consecutive patients with colorectal carcinoma gave
informed consent to enter the trial. Patients received potas-
sium iodide and potassium perchlorate to block thyroid
uptake of antibody. Skin testing for allergey to the antibody
was carried out as described previously (Begent et al., 1986).
Following this 1 mCi of '25I-labelled antibody was injected
intravenously and an attempted curative resection was car-
ried out 4-10 days later. Of the 50 patients studied 24 were
male and 26 female. The median age was 69 years (range
38-82 years). Seven patients had synchronous tumours mak-
ing a total of 57 tumours. There were 41 primary resections
and nine second look laparotomies. Eleven patients were
randomised to FMlDIO and 39 to A5B7. After a preliminary
analysis of results, FMlDIO was abandoned.
Monoclonal antibodies
FMIDIO This is a mouse monoclonal IgGl antibody to
fetal colonic microvillus membrane which showed a good
localisation to human carcinoma xenografts in nude mice
and appeared immunohistochemically to bind to tumour cells
(Hennigan et al., 1988).
ASB7 This is a mouse monoclonal IgGl antibody to car-
cinoembryonic antigen (anti-CEA) (Harwood, 1986; Pedley,
1987) which has been used extensively for external imaging of
occult colorectal cancer recurrence.
Peroperative scanning and expression ofresults
A 1 cm diameter cadmium telluride probe (Neoprobe Cor-
poration, OH, USA) inside a sterile plastic sheath was used
to detect radioactive counts over normal colon, tumour and
mesentery. Counts were made in triplicate at the start of the
laparotomy, and again after mobilisation and after resection
of the tumour. The precise sites where the probe counts had
been made were marked on the specimen for correlation with
well counts and histology. With the wide range of radioac-
tivity in both normal colon and tumour, in order to compare
results between patients a ratio of tumour to normal colon
counts was taken. To determine the value of tumour:normal
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colon ratio that constituted a significant uptake of antibody,
the 99% confidence limits of normal colon were calculated.
Where background counts over normal colon were low, the
99% confidence limits were higher. For example, counts over
normal colon in one patient gave a mean ± standard devia-
tion of 18 ± 3 c.p.s. (coefficient of variation = 16.6%) with
an upper 99% confidence limit of 27 c.p.s. (1.5 x mean).
With a shorter interval between injection and operation, the
background counts were higher and the confidence limits
were lower. For example mean ± s.d. of 430 ± 48 c.p.s.
(coefficient of variation= 11.1%) gave a 99% confidence
limit of 574 c.p.s. (1.3 x mean). From all the individual
calculations the upper 99% confidence limit of counts over
normal bowel was up to 1.5 times the mean count. Therefore
in keeping with previous studies (Aitken, 1984) we have
taken a ratio of greater than 1.5 times the value over normal
colon to indicate a pathologically high concentration of
antibody.
Analysis ofspecimen
The marked sites on the specimen were dissected out and
divided. Part was weighed and put into a well counter in the
laboratory to measure radioactivity as a percentage of the
injected dose per kilogram (Pedley, 1987). The remainder was
sent for histological studies, including morphological
appearances and immunoperoxidase staining to demonstrate
the site of antibody. In order to assess the smallest quantity
of tumour that could be detected, four tumours were sub-
divided into multiple small pieces which were placed in the
submucosa of normal colon of the same specimen and counts
recorded. The smallest pieces of tumour that gave a count at
least 1.5 times that of normal colon were collected and
weighed separately.
Statistical analysis
Differences between different groups were analysed using the
non-parametric Mann-Whitney U test and results expressed
as median and range. The variation of repeated results from
one tissue in one patient was normally distributed and
therefore parametric statistical analysis of confidence limits
and errors were calculated.
Results
All tumours were adenocarcinoma of colon or rectum. There
was a preponderance of more advanced tumours with only
10/57 (17%) being Dukes' stage A, although six of these were
in the FMID0 group. Sixty-five per cent of tumours were in
the descending colon or rectum and the majority of patients
had moderately differentiated tumours (Table I).
Table I Tumour stage and differentiation of 57 colorectal
carcinomas
FMlDJO ASB7
Dukes' stage
A 6 4
B 4 18
C 3 22
Total 13 44
Differentiation
Well 0 4
Moderate 11 34
Poor 2 6
Total 13 44
Table II Median and range of results of radioactivity in all patients
measured both by hand-held gamma counting probe and well
counter
FMlD1O A5B7
Probe (c.p.s.)
Normal colon 170 (17-437) 58 (15-286)**
Tumour 352 (24-772) 233 (50-600)**
Well counter (%i.d. kg-')
Blood 0.95 (0.1-3.6) 0.40 (0.04-2.9)*
Normal colon 0.23 (0.05-0.88) 0.42 (0.05-1.25)
Tumour 0.30 (0.06-1.15) 1.40 (0.4-10.5)*
Probe
Tumour:colon ratio 1.85 (0.75-7.7) 3.3 (1.1-13.8)
Ratio >1.5:1 9/13 (69%) 43/44 (98%)
*P<0.01, **P<0.001, Mann-Whitney U test.
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Figure 1 Tumour:normal colon ratios. Sixty-nine per cent (9/13)
of FMIDIO labelled patients (0) and 98% (43/44) of A5B7
labelled patients (0) took up antibody with a tumour:normal
colon ratio of more than 1.5:1 (---).
Radioactivity uptake by tumours
Nine out 13 (69%) FM1DIO labelled tumours took up
significant amounts of antibody whereas 43 out of 44 (98%)
of A5B7 labelled tumours took up antibody (P<0.01, x2
with Yates' correction). Using the hand-held gamma detec-
ting probe the median and range of counts over normal
colon in situ was 170 (17-437) c.p.s. for FMIDIO compared
to 58 (15-286) c.p.s. for A5B7 (P<0.001). Similarly there
were higher counts over tumour for FMIDI0 with a median
352 (24-772) c.p.s. compared to 233 (50-600) c.p.s. for
A5B7 (Table II). The median tumour:normal colon ratio for
FMID1O was 1.85 (0.75-7.7) compared to 3.3 (1.1-13.8) for
A5B7 (P<0.001). The individual peroperative results of
tumour:normal colon ratio were correlated with the time
interval from injection of antibody until laparotomy (Figure
1). The tumour:normal colon ratios for both antibodies were
independent of time with significant uptake as little as 70
hours following injection of A5B7.
The one tumour which failed to take up A5B7 in
significant amounts was positive on immunoperoxidase stain-
ing for CEA and was in a patient with a very high CEA of
2,300ILg-'. The patients whose tumours failed to take up
FMIDl0 had normal CEA levels. There was no correlation
between peroperative serum CEA, Dukes' stage or his-
tological differentiation and the tumour:colon ratio for either
antibody.
Analysis ofspecimen
The minimum weight of tumour detectable experimentally on
the specimen depended on the degree of uptake of antibody.
With a tumour:colon ratio of 10:1 a mean ± s.e.m. of 30 +
4 ig of tumour could be detected compared to 140 ± 20 Lg
when the ratio was only 2:1.ANTI-FETAL MICROVILLUS AND ANTI-CEA ANTIBODIES 893
Well counts
Excretion of FMID1O was slower than A5B7. At the time of
surgery, the median radioactivity of blood in a well counter
was significantly higher for patients given FMID1O at 0.95
(0.1-3.6) % of the injected dose per kilogram (%i.d. kg-')
compared to only 0.4 (0.04-2.0) for A5B7 (P<0.01) (Figure
2). For FMIDIO patients, the median radioactivity was
significantly higher in blood than in tumour (0.95 (0.1-3.6)
versus 0.3 (0.06-1.1) %i.d. kg-', P<0.05). However, for
A5B7 patients, radioactivity in tumour was higher than in
blood as little as 3 days after injection of antibody (median
tumour activity 1.4 (0.4-10.5) versus 0.4 (0.04-2.9)
%i.d. kg-' for blood P<0.01).
Comparison ofprobe with well counts
To assess if the hand-held probe gave comparable readings to
the conventional well counter, results of tumour:normal
colon ratios of the resected specimen for each method were
correlated by linear regression (Figure 3). There was a linear
correlation with a correlation coefficient r of 0.78 (P<0.001).
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Figure 3 Correlation of ratios of tumours:normal colon radio-
activity between gamma probe and well counter in all 50 patients
(correlation coefficient r = 0.78, P<0.001).
Immunohistochemistry
Immunoperoxidase staining of the specimens showed that
FM1D1O localised predominantly to the cell surface and
A5B7 localised in the matrix around the tumour cells which
produce CEA.
Clinical and histological correlates
Eight patients had advanced local disease with invasion of
bladder, small bowel or stomach (one FM1D10, seven
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Figure 2 Using FMlD10 levels of radioactivity antibody were
higher in blood (@) than tumour (0) even after 10 days. Using
A5B7 levels of radioactive antibody in the tumour exceeded those
in blood in as little as 3 days after injection of antibody.
A5B7). In all eight patients high counts correlated with
tumour being present and, by ensuring resection margins did
not demonstrate high uptake of antibody, they were all
reported as being clear histologically. Using A5B7 the loca-
tion of a primary tumour was found in a patient with an
impalpable Dukes' A tumour, and a clinically normal distal
resection margin which was found to have a high radioactive
count was histologically invaded with tumour.
Probe counts were recorded over the root of the mesentery
of 20 Dukes' C carcinomas of which 16 had high counts
suggestive of lymphatic spread of tumour. The four patients
with normal counts all had A5B7. One was the patient who
failed to take up antibody into the primary tumour; two
others had histological involvement of only 1:8 and 1:15
nodes with the involved node not being in the root of the
mesentery and the fourth had 3:6 nodes invaded including
the root of the mesentery.
False positives
There were three false positives in the A5B7 group: a his-
tologically inflamed but benign lymph node, a benign
duodenal ulcer found incidentally at laparotomy and one
lateral pelvic wall after excision of a Dukes' C carcinoma of
the rectum. Further biopsy of this hot spot showed only
benign tissues.
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Discussion
The use of an intra-abdominal cadmium telluride gamma
counting probe has been validated as a reliable method of
detecting '25I-labelled antibody, and gives good correlation
with laboratory results obtained using a well counter. How-
ever, the choice of antibody for this technique appears to be
critical. Numerous antibodies have been used to localise
human and animal colonic cancers (Mach et al., 1980; Pimm
et al., 1985; Epenetro et al., 1986; Balantyne et al., 1988) and
some authors have suggested that uptake is more dependent
on host factors than the characteristics of the antibody
(Balantyne et al., 1988).
A5B7 appears to represent a significant improvement on
all previously used antibodies. The difference in uptake
between FMIDIO and A5B7 demonstrates that A5B7 is
more appropriate for the specific requirements that we have
made, namely that it is taken up into nearly all tumours,
within 3 days, with a high tumour:normal colon ratio so that
small quantities of tumour can be detected. Previous authors
have suggested that a tumour to normal colon ratio of
greater than 1.5:1 is indicative of tumour (Aitken et al.,
1984). Using A5B7, 98% of tumours had a ratio of more
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than 2:1. Using FMIDI0 anti-fetal microvillus antibody only
69% of tumours had a ratio of more than 1.5:1. It is possible
that results with FMlD0 would have been better if a longer
period had been left between injection of antibody and
laparotomy, as even at 10 days there was more radioactivity
in blood than in tumour. Other workers using baboon polyc-
lonal anti-CEA anibodies or anti-cell surface antigen
antibodies (Aitken et al., 1984; Martin et al., 1985, 1986;
O'Dwyer et al., 1986, 1987) have reported similar results to
FMlDIO with 72-76% uptake, but they have used a longer
interval of up to 21 days between injection and laparotomy.
In this series, most additional information was obtained in
patients with locally advanced disease and it was felt that a
delay of up to three weeks was a disadvantage, particularly
where there may be a risk of obstruction. Consequently, the
use of FM1DI0 was abandoned after preliminary assessment
of 13 tumours.
In contrast, A5B7 anti-CEA monoclonal antibody was
taken up by 98% of tumours, with good differentiation
between tumour and normal tissues possible in as little as 3
days. The only patient who failed to localise the antibody
had a serum CEA of 2,300ytg 1' and it is postulated that in
this instance antibody bound to serum CEA rather than
tumour CEA. Nevertheless, one patient with a serum CEA of
7,000fig 1' was still able to localise the antibody in tumour.
With a ratio of tumour:normal colon of 2:1, tumour of the
order of 140 Lg can be detected and this is equivalent to the
size of a small lymph node. It must be accepted that micros-
copic residual tumour may not be detected with the probe.
However, having removed the bulk of tumour to less than
0.1 g we are investigating the theoretical possibility that
where there has been good uptake of antibody into tumour,
one might give further doses ofantibody as adjuvant therapy
either bound to a high dose of radioactivity or to a
chemotherapeutic agent (Lederman, 1989).
The time taken during operation to count radioactivity of
the different tissues adds between 5 and 10 min to the proce-
dure. In practice, counts are not taken over all lymph nodes
as the factor which might influence surgery is whether the
highest nodes or tissues at the resection margins are involved.
This method offers a quick and simple way for the surgeon
to obtain information, rather than awaiting the results of
multiple frozen sections.
This technique gave information additional to clinical
assessment in approximately 20% of patients which is in
keeping with other studies. An interesting observation in
these patients is that while in two cases this information led
to more radical surgery being performed, more conservative
procedures were undertaken in eight patients. The benefits
therefore need to be assessed not only in reducing local
recurrence and long-term survival, but also in preventing
unnecessary debilitating procedures for inflammatory rather
than neoplastic change. Only long-term follow-up and
absence of late local recurrence will confirm this as a benefit.
False positives and false negatives are a concern and more
detailed information is being sought in further clinical
studies. The false positive over an active duodenal ulcer may
be related to the increased blood supply of this inflammatory
lesion. The patient is alive and well 2 years after surgery with
no sign of recurrence. In this context, the false positive
reading over the lymph node in one patient was also related
to a tumour with considerable surrounding inflammation
histologically. In this series two patients with carcinoma in
active ulcerative colitis had significantly higher uptake into
tumour than into inflamed tissues, and we therefore conclude
that the antibody does not specifically localise to an area of
inflammation. The other false positive was in the lateral
pelivic wall following anterior resection. Biopsy of this area
was histologically clear, but we have given the patient post-
operative radiotherapy to the area. Where tumours invaded
adjacent structures there was no difficulty in distinguishing
malignant disease from inflammatory disease.
While continued studies are necessary to define in whom
peroperative radioimmunolocalisation is going to be of
greatest benefit, we have both validated the technique and
described the use of anti-CEA monoclonal antibody (A5B7)
which has significant advantages over both FM1D1O and all
previously described antibodies. Results so far suggest that
the probability of complete local excision is increased.
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